6) Safe administration along with blood thinners
a) Combined administration of nattokinase NSK-SD®, heparin and anti-platelet drugs:
In a clinical trial, adult patients (average age 53.3) with acute ischaemic stroke were orally administered 2,000 FU nattokinase NSK-SD® 3 times (total 6,000 FU) a day at 8-hour interval for a period of 7 days. During these 7 days, the patients were also administred 0.4ml low molecular weight heparin (anti-factor Xa, 3,800 IU) 2 times a day by hypodermic injection and low-dose aspirin (150 – 325mg) or clopidogrel. Heparin (anticoagulant drug), aspirin and clopidogrel (anti-platelet drugs) are all blood thinners. In this study, all patients were hospitalized within 6 hours of stroke occurrence and the treatment was administered after hospitalisation. The overall efficacy data suggests that nattokinase NSK-SD® does not lead to progression of underlying stroke. Instead, the combined administration is proposed to enhance fibrinolysis (breaking down of blood clots) and the beneficial effects on stroke patients were observed.
b) Combined administration of nattokinase NSK-SD® and warfarin:
In a clinical trial, patients with CVDs who were taking warfarin potassium tablets at a maintenance dose (1.5 < PT-INR < 3.0) were orally administered 2 doses of 1,700 FU nattokinase NSK-SD® after breakfast and dinner daily for 6 months. Some of these patients noticed an improvement in clinical symptoms (i.e. shortness of breath, cold hands and feet) and biochemical profiles, which includes activated partial thromboplastin time (aPTT), prothrombin time (PT), D-dimer and plasmin inhibitor complex (PIC). All patients taking nattokinase NSK-SD® did not have side effects. This study suggests that nattokinase NSK-SD® is safe and effective for CVD patients who are taking warfarin.